Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTern Regulatory News (TERN)

Share Price Information for Tern (TERN)

Share Price is delayed by 15 minutes
Get Live Data
1.20    -0.11 (-8.40%)
Bid:
1.10
Ask:
1.30
Spread: 0.20 (18.182%)
Market Cap: £10.27m
TERN Live PriceLast checked at - London Stock Exchange

Intraday Tern Share Chart

Device Authority Convertible Loan Notes Investment

22 May 2026 07:00

RNS Number : 3552F
Tern PLC
22 May 2026
 

22 May 2026

 

Tern Plc

 

("Tern" or the "Company")

 

Investment in Device Authority Convertible Loan Notes

 

Tern Plc (AIM:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things ("IoT") technology businesses, announces that it has invested US$280,000 (approximately £209,000) in new unsecured convertible loan notes (the "CLNs") issued by Device Authority Limited ("Device Authority"). The investment in the Device Authority CLNs will be funded from the proceeds of the Company's recent Open Offer.

 

The CLNs carry an interest rate of 8 per cent. per annum and the CLNs' principal amount and accrued interest are convertible on either a change of control of Device Authority, or a fundraising of at least US$5 million (a "Qualifying Fundraise") undertaken by Device Authority, or, if neither have occurred on 30 June 2027. On a change of control, the CLNs are convertible at a three times multiple to their face value and the value of accrued interest. On a Qualifying Fundraise the CLNs are convertible at a 25 per cent discount to the Qualifying Fundraise price. If neither a change of control nor a Qualifying Fundraise has taken place, the CLNs will mature on 30 June 2027.

 

As at 30 June 2025, the date of Tern's last published book valuation, Tern's holding in Device Authority had a total unaudited book value of £4.0 million. Following the issue of the CLN, Tern's equity holding in Device Authority will be unchanged and Tern will continue to hold approximately 25.3% of Device Authority's equity (before any dilution on exercise of share options), although now with a CLN holding of approximately £0.21 million.

 

As part of the same overall funding round, Device Authority is in the process of raising up to US$1.6 million of funding from existing investors through the issue of CLNs on the same terms.

 

Jane McCracken, Interim Non-Executive Chair of Tern, said: "We are pleased to be able to provide this further funding to Device Authority, which is part of a larger fundraise by the business to ensure they have sufficient working capital to service significant contracts expected in the near term. We remain very excited by the potential of Device Authority and our other portfolio companies, and are focused on realising value from them as soon as is appropriate."

 

Further information on Device Authority

 

Device Authority is a global leader in Identity and Access Management ("IAM") for the IoT; focused on the automotive, medical device ("IoMT") and industrial ("IIoT") sectors. Device Authority's KeyScaler™ platform provides zero touch provisioning and complete automated lifecycle management for securing IoT devices and data at scale, with frictionless deployment across device provisioning, authentication, credential management, policy based end-to-end data security/encryption and secure OTA (over the air) and HSM (hardware security module) updates.

 

Based on Device Authority's latest statutory accounts for the year ended 31 December 2025, as at that date it had net assets of approximately £11,609,000 and incurred a loss for the year of approximately £1,750,000. Given the historic and statutory nature of these figures, Tern does not consider this to be representative of the current business, trading performance and prospects of Device Authority.

 

Enquiries

 

Tern Plc

Jane McCracken (Interim Non-Executive Chair)

via IFC Advisory

 

Allenby Capital Limited

(Nominated Adviser and Broker)

Alex Brearley / Ashur Joseph (Corporate Finance)

Kelly Gardiner (Sales and Corporate Broking)

 

Tel: 0203 328 5656

 

IFC Advisory

(Financial PR and IR)

Tim Metcalfe

Graham Herring

Florence Staton

 

Tel: 0203 934 6632

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPUQAAUPQGQG
Date   Source Headline
8th Jun 20267:00 amRNSNotice of AGM
29th May 20265:00 pmRNSTotal Voting Rights
26th May 20267:00 amRNSInvestment in Talking Medicines CLNs
22nd May 20267:00 amRNSDevice Authority Convertible Loan Notes Investment
19th May 20267:00 amRNSPlacing to raise £222,000
12th May 20267:00 amRNS-RDevice Authority Strategic Partnership
8th May 202612:53 pmRNSResult of GM & Update on Open Offer
8th May 20267:00 amRNSResults of Open Offer
21st Apr 20267:00 amRNSOpen Offer and Notice of General Meeting
31st Mar 20265:00 pmRNSTotal Voting Rights
5th Mar 20267:00 amRNSExtension of loan facility agreement
3rd Mar 20267:00 amRNSResults of Open Offer
13th Feb 20267:00 amRNSOpen Offer at 0.40p to raise up to £384,408
5th Feb 20267:00 amRNS-RTern Notes Automotive Momentum at Device Authority
15th Jan 20267:00 amRNSUpdate regarding SVV2
8th Jan 20267:00 amRNSInvestor Presentations
23rd Dec 20257:00 amRNS-ROnline Investor Presentation and Q&A Session
23rd Dec 20257:00 amRNS-ROnline Investor Presentation and Q&A Session
12th Dec 20257:00 amRNSIssue of Talking Medicines Convertible Loan Notes
28th Nov 20257:00 amRNSUpdate regarding capital commitment to SVV2
25th Nov 20257:00 amRNSTalking Medicines CLN Modifications
31st Oct 20253:35 pmRNSTotal Voting Rights
15th Oct 20257:00 amRNSResults of Open Offer
9th Oct 20257:00 amRNSRemuneration Reductions & Distribution Commitment
29th Sep 20257:00 amRNSOpen Offer to raise up to £642,486
15th Sep 20257:00 amRNSExtension of Loan Facility Term
4th Sep 20257:00 amRNSInterim results for the six months to 30 June 2025
1st Sep 20257:00 amRNSAppointment of shareholder relations adviser
31st Jul 20254:34 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSResults of underwritten Open Offer & TVR
24th Jul 20257:00 amRNSReceipt of Bridging Loan
14th Jul 20257:00 amRNSUnderwritten Open Offer to raise £642,486
30th Jun 202512:07 pmRNSResult of AGM
13th Jun 20257:00 amRNSDirector Share Purchase
11th Jun 20257:00 amRNSDirector Share Purchase
6th Jun 20257:00 amRNSNotice of AGM and Director Retirement
5th Jun 20257:00 amRNSResults for the year ended 31 December 2024
30th May 20255:39 pmRNSTotal Voting Rights
7th May 20257:00 amRNSResults of Underwritten Open Offer
24th Apr 20257:00 amRNSPurple Transform appointment
17th Apr 20257:00 amRNSUnderwritten Open Offer to raise £340,140
11th Mar 20257:00 amRNS-RDevice Authority Microsoft & CyberArk Partnership
11th Mar 20257:00 amRNS-RSure Ventures Update
28th Feb 20255:00 pmRNSTotal Voting Rights
21st Feb 20257:00 amRNSPlacing to raise £221,154
14th Jan 20257:30 amRNS-RProgressive Equity Research Report
10th Jan 20257:00 amRNSInvestor Presentations
2nd Jan 20257:00 amRNSInvestment in Sure Ventures plc
31st Dec 20241:30 pmRNSTotal Voting Rights
23rd Dec 202411:39 amRNSDevice Authority update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.